Expression pattern of anti-apoptotic protein survivin in dysplastic nevi

Neoplasma

Volumn 56, Issue 2, 2009, Pages 130-135

  Adamkov, M ^a   Lauko, L ^b   Balentova, S ^a   Pec, J ^a   Pec, M ^a   Rajcani, J ^b  

^a University Teaching Hospital in Martin   (Slovakia)

^b Alpha Medical as   (Slovakia)

Author keywords

Dysplasia; Immunohistochemistry; Melanoma; Nevi; Survivin

Indexed keywords

ANTIBODY; ANTIGEN; PROTEIN; SURVIVIN; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ANTIBODY LABELING; ARTICLE; CANCER DIAGNOSIS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLONE; CYTOPLASM; DYSPLASIA; DYSPLASTIC NEVUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS CELL; PROTEIN EXPRESSION; CELL NUCLEUS; CHEMISTRY; METABOLISM; PATHOLOGY;

CELL NUCLEUS; CYTOPLASM; DYSPLASTIC NEVUS SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS;

EID: 65649131590     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_02_130     Document Type: Article

References (35)

1. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005; 4: 139-163. (Pubitemid 41351311)
2. Daniel PT, Schulze-Osthoff K, Belka C et al. Guardians of cell death: the BCL-2 family proteins. Essays Biochem 2003; 39: 73-88. (Pubitemid 37457072)
3. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-450. doi:10.1016/j. molmed.2006.07.007 PMid:16899408 (Pubitemid 44291571)
4. Shi Y. Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 2006; 18: 677-684. doi:10.1016/j.ceb.2006.09.006 PMid:17046227
5. Verhagen AM, Ekert PG, Pakush M et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53. doi:10.1016/S0092-8674(00)00009-X PMid:10929712
6. Du C, Fang M, Li L. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42. doi:10.1016/S0092-8674(00)00008-8 PMid:10929711
7. Wallach D, Varfolomeev EE, Malinin NL et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17: 331-367. doi:10.1146/annurev.immunol. 17.1.331 PMid:10358762 (Pubitemid 29241128)
8. Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISCS and beyond. Cell Death Differ 2003; 10: 26-35. doi:10.1038/sj.cdd.4401186 PMid:12655293
9. Russel JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323-370. doi:10.1146/annurev.immunol.20.100201.131730 PMid:11861606
10. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001; 20: 3-11. doi:10.1023/A:1013123532723 PMid:11831644 (Pubitemid 34074673)
11. Helmbach H, Rossmann E, Kern MA et al. Drug-resistance in human melanoma. Int J Cancer 2001; 93: 617-622. doi:10.1002/ijc.1378
12. Meier F, Satyamoorthy K, Nesbit N et al. Molecular events in melanoma development and progression. Front Biosci 1998; 3: D1005-D1010.
13. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-913. doi:10.1038/nature03485 PMid:15829965 (Pubitemid 40559004)
14. Bartkova J, Horejsi Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870. doi:10.1038/nature03482 PMid:15829956 (Pubitemid 40558993)
15. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-53. doi:10.1038/nrc968 PMid:12509766
16. Bowen AR, Hanks AN, Allen SM et al. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003; 120: 48-55. doi:10.1046/j.1523-1747.2003.12010.x PMid:12535197 (Pubitemid 36120970)
17. Hoffman WH, Biade S, Zilfou JT et al. Transcriptional Repression of the Anti-apoptotic survivin Gene by Wild Type p53. J Biol Chem 2002; 277: 3247-3257. doi:10.1074/jbc.M106643200 PMid:11714700 (Pubitemid 34953189)
18. Raj D, Liu T, Samadashwily G et al. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis 2008; 29: 194-201. doi:10.1093/carcin/bgm219 PMid:17916908
19. Piras F, Murtas D, Minerba L et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathol 2007; 50: 835-1822 doi:10.1111/j.1365-2559.2007.02695.x PMid:17543072 (Pubitemid 46850069)
20. Bowen AR, Hanks AN, Murphy KJ et al. Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatol 2004; 26: 177-181. doi:1 0.1097/00000372-200406000-00001 PMid:15166502 PMCid:2292412
21. Li F. Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29. doi:10.1002/jcp.10327 PMid:12942537
22. Velculescu VE, Madden SL, Zhang L et al. Analysis of human transcriptomes. Nat Genet 1999; 23: 387-388. doi:10.1038/70487 PMid:10581018
23. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-252. doi:10.1101/gad.13.3.239
24. Grossman D, McNiff JM, Li F et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melamoma. J Invest Dermatol 1999; 113: 1076-1081. doi:10.1046/j.1523-1747.1999.00776.x PMid:10594755 (Pubitemid 30013356)
25. Pennati M, Binda M, De Cesare M et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melamoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004; 25: 1129-1136. doi:10.1093/carcin/bgh107 PMid:14764461 (Pubitemid 38968040)
26. Takeuchi H, Morton DL, Elashoff D et al. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 2005; 117: 1032-1038. doi:10.1002/ijc.21267 (Pubitemid 41688581)
27. Dohi T, Beltrami E, Wall NR et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-1127. (Pubitemid 39578701)
28. Ding Y, Prieto VG, Zhang PS et al. Nuclear expression of the antiapoptoptic protein survivin in malignant melanoma. Cancer 2006; 106: 1123-1129. doi:10.1002/cncr.21727 PMid:16456815 (Pubitemid 43297352)
29. Alonso SR, Ortiz P, Pollán M et al. Progression in Cutaneous Malignant Melanoma is Associated with Distinct Expression Profiles. Am J Pathol 2004; 164: 193-203.
30. Florell SR, Bowen AR, Hanks AN et al. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol 2005; 32: 45-49. doi:10.1111/j.0303-6987.2005.00242.x PMid:15660660 PMCid:2292117
31. Vetter CS, Miller-Blech K, Schrama D et al. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch Dermatol Res 2005; 297: 26-30. doi:10.1007/s00403-005-0572-x PMid:15906050 (Pubitemid 41380679)
32. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions. Am J Dermatol 2008; 30: 117-122. doi:10.1097/DAD.0b013e3181624054 PMid:18360113
33. Alanko T, Rosenberg M, Saksela O. FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal melanocytes. J Invest Dermatol 1999; 113: 111-116. doi:10.1046/j.1523-1747.1999.00636.x PMid:10417628 (Pubitemid 29328168)
34. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 2001; 38: 225-262. doi:10.1080/20014091084218 PMid:11451209 (Pubitemid 32614076)
35. Tucker MA, Halpern A, Holly EA et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277: 1439-1444. doi:10.1001/jama.277.18.1439 PMid:9145715